International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: eyeThe American Brachytherapy Society recommendations for brachytherapy of uveal melanomas
Introduction
Enucleation had been considered the standard treatment for patients with posterior uveal melanoma. In an effort to preserve vision and the globe, episcleral plaque radiotherapy has become a commonly used alternative. Moore first used radon seed brachytherapy to preserve vision for a monocular patient with uveal melanoma (1). Stallard also tried implanting seeds directly into the tumor, but went on to develop cobalt-60 (60Co) plaque radiotherapy (2). Since that time, a number of other radioisotopes (radionuclides), including gold-198, iodine-125, Ru-106/Rh-106, iridium-192, and palladium-103, have been used for episcleral radiotherapy with varying results from retrospective studies 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24. In an effort to resolve some of the controversies, the Collaborative Ocular Melanoma Study (COMS) Group performed a nationwide, multi-institutional, prospective randomized clinical trial to compare efficacy of enucleation vs. I-125 eye plaque radiotherapy for medium-sized choroidal melanomas and recently reported the preliminary results 25, 26. Other than the COMS guidelines, there are no standardized procedures for episcleral eye plaque use. The American Brachytherapy Society (ABS) therefore formed a panel to issue guidelines for the use of brachytherapy for choroidal melanomas.
Section snippets
Methods and materials
Selected members of the ABS with expertise in choroidal melanoma brachytherapy performed a literature review that, supplemented by their clinical experience, allowed formulation of specific recommendations and directions for future investigation in choroidal melanomas. These recommendations were made by consensus opinion and supported by published data whenever possible. In addition, an external multispecialty panel of recognized experts in the field reviewed the consensus recommendations and
Results
Episcleral plaque brachytherapy is a complex procedure, and the ABS recommends that these procedures should only be undertaken in specialized medical centers with expertise in this sophisticated treatment program. The results of the deliberation of the panel and the ABS recommendations are given in the following sections.
Conclusion
Brachytherapy represents an effective means of treating patients with choroidal melanomas. Guidelines are established for the use of brachytherapy in the treatment of choroidal melanomas. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose reporting policies. These guidelines will be modified as further clinical results become available.
Acknowledgements
The authors wish to express their gratitude to Mr. David Carpenter for editorial assistance. The authors acknowledge the support of the Board of Directors of the American Brachytherapy Society and thank Drs. Beth Erickson and Marvin Rotman for their valuable suggestions.
References (120)
Radiation therapy for choroidal melanoma (therapeutic review)
Surv Ophthalmol
(1997)- et al.
Treatment of choroidal melanoma with I-125 plaque
Int J Radiat Oncol Biol Phys
(1993) - et al.
Palladium-103 plaque radiotherapy for choroidal melanoma. An 11-year study
Int J Radiat Oncol Biol Phys
(2002) - et al.
Palladium-103 plaque radiotherapy for uveal melanoma. Clinical experience
Ophthalmology
(1994) - et al.
Palladium-103 plaque radiotherapy for choroidal melanomaResults of a 7-year study
Ophthalmology
(1999) - et al.
The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas
Int J Radiat Oncol Biol Phys
(2001) - et al.
Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture
Ophthalmology
(1993) - et al.
Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma
Int J Radiat Oncol Biol Phys
(2001) Uveal melanoma—Conservative treatment
Hematol Oncol Clin N Am
(2001)- et al.
Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma
Ophthalmology
(1996)